Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,616.50
Bid: 1,582.00
Ask: 1,695.00
Change: 0.00 (0.00%)
Spread: 113.00 (7.143%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain to spend $5 billion on vaccines and bear liability, watchdog says

Wed, 16th Dec 2020 00:01

LONDON, Dec 16 (Reuters) - Britain has agreed to spend 3.7
billion pounds ($4.93 billion) on COVID-19 vaccines and in most
cases will bear the liability if claims are made against the
pharmaceutical firms involved, the National Audit Office (NAO)
said on Wednesday.

The government has agreed supply deals for 357 million doses
of seven different candidate shots, but has not gone into detail
about how much it has spent or indemnity agreements, citing
commercial confidentiality around the contracts.

The NAO said the business ministry had signed firm deals for
five of the candidates, including the Pfizer/BioNTech shot which
has already been approved and is being rolled out, as well as
those developed by Oxford/AstraZeneca, France's Valneva, Novavax
and Moderna.

Britain also has deals in principle for
Sanofi/GlaxoSmithKline's shot as well as Johnson & Johnson's
candidate.

The government has invested in the development and clinical
trials of some of the vaccines it has agreed supply deals for,
and agreed to indemnify the firms against liability.

Those agreements mean that in four of the five finalised
contracts, there was no cap on how much the government could pay
if there is a successful claim against one of the companies, the
report said.

The NAO said the business ministry agreed upfront payments
of 914 million pounds on the five contracts it has signed, prior
to regulatory approval of any of the vaccines.

Only one of the contracts provides for a full refund of the
upfront payment if the vaccine fails to achieve regulatory
approval.

The NAO noted that the government had worked "quickly and
effectively" to secure vaccines, demonstrated when Britain
became the first country in the world to deploy Pfizer's
vaccine last week.

"We have worked at a pace and scale never been done before
to ensure the British public receive a vaccine that meets strict
safety standards as quickly as possible," a spokeswoman for the
business ministry said.

In all, the total cost of purchasing and deploying vaccines
was uncertain, the NAO said, but estimated that it could cost up
to 11.7 billion pounds.

($1 = 0.7505 pounds)
(Reporting by Alistair Smout; Editing by Tom Brown)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.